News about Fibrogen Inc

Navigating Transformation: FibroGen?s Strategic Sale Enhances Shareholder Value Post-Oncology Advancements
Feb 20 2025
In an assertive move signaling a strategic refocus, FibroGen, Inc. (NASDAQ: FGEN) announced the sale of its China subsidiary to pharmaceutical titan A...

FibroGens Promising Advances in Oncology Pioneering Trials for Pancreatic Cancer, mCRPC, and Innovative Collaborat...
Jul 30 2024
FibroGen, Inc. (NASDAQ: FGEN), a rising force in the oncology landscape, has recently unveiled significant milestones in its clinical trials and colla...

FibroGens FG-3246 Shows Promise in Metastatic Castration-Resistant Prostate Cancer An Assessment of Recent Developments
Jun 18 2024
In recent announcements, FibroGen, Inc. has revealed significant advancements in the development of FG-3246, a potential innovative anti-CD46 antibody...

FibroGen Collaborates with Regeneron Pharmaceuticals to Advance Immuno-Oncology Treatment for Solid Tumors
Jun 03 2024
SAN FRANCISCO, June 03, 2024 - FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company, has announced a clinical trial supply agreement wit...

*SAN FRANCISCO, May 23, 2024* - FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company committed to pioneering therapeutic advancements for serious unmet medical needs, is celebrating a significant milestone with the announcement of positive interim data from the dose escalation portion of the Phase 1b/2 study of FG-3246 (FOR46). This study is conducted by the Universit...
May 23 2024
FibroGen Showcases Clinical Breakthroughs in Cancer Therapy at ASCO 2024 and Upcoming KOL Investor Event SAN FRANCISCO, May 23, 2024 - FibroGen, Inc...

Promising Results of FG-3246 in Phase 1 Monotherapy Study for Metastatic Castration-Resistant Prostate Cancer
Apr 02 2024
This article provides an overview of the topline results from the Phase 1 study conducted by FibroGen, Inc. and sponsored by Fortis Therapeutics. The...

FibroGen Assumes Full Control of Revolutionary Anemia Drug, Roxadustat, Except in China and South Korea; Retention of China Agreement Highlights Continued Focus on Expanding Reach in Largest CKD Market
Feb 26 2024
FibroGen, a leading biopharmaceutical company, has recently announced that it has regained all rights to its innovative therapeutic drug, Roxadustat, ...

FibroGen*s Pamrevlumab Shows Promise in Pancreatic Cancer Clinical Program
Feb 05 2024
FibroGen, Inc. (NASDAQ: FGEN) has recently announced its plans to host Part I of a virtual KOL (Key Opinion Leader) investor event series on February ...

Fibrogen Inc Witnesses Notable 155.062% Surge in Revenue Over Three-Month Fiscal Period Ending Sep 30, 2023
Nov 07 2023
Fibrogen Inc, a biotech company operating in a seasonal nature of business, has recently reported some positive changes in its financial per...

Fibrogen Inc*s Financial Woes Deepen: Innovation Takes a Hit in Recent Fiscal Period
May 09 2023
Fibrogen Inc is a pharmaceutical and biotechnology company that specializes in the development of innovative therapies for the treatment of serious an...